ProCE Banner Activity

TROPHY-U-01 Cohort 2: Sacituzumab Govitecan After Checkpoint Inhibition in Platinum-Ineligible Metastatic Urothelial Cancer

Capsule Summary
Conference Coverage
Slideset

Sacituzumab govitecan showed encouraging antitumor efficacy in platinum-ineligible patients with mUC with progression following ICI therapy.

Released: February 22, 2023

Expiration: February 21, 2024

Begin Activity

Share

Provided by

ProCE Banner

Supporters

This activity is supported by educational grants from

Bayer HealthCare Pharmaceuticals Inc.

Exelixis, Inc.

Gilead Sciences, Inc.

Pfizer, Inc.